Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Withdrawn 1Terminated 1Suspended 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 19Prostatic Neoplasms 9Breast Neoplasms 9Melanoma 8Colorectal Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Pancreatic Neoplasms 6Neoplasm Metastasis 6Ovarian Neoplasms 5Carcinoma, Hepatocellular 5Triple Negative Breast Neoplasms 4Solid Tumors 4Myelodysplastic Syndromes 4Leukemia, Myeloid, Acute 4Glioblastoma 4Carcinoma, Renal Cell 4Stomach Neoplasms 3Multiple Myeloma 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pain 2Mesothelioma 2Lymphoma, T-Cell 2Liver Neoplasms 2

Interventions

resiniferatoxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × INDUSTRY × Pain, Intractable × Clear all
NCT05067257 2024-03-18

Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer

Sorrento Therapeutics, Inc.

Phase 2 Suspended
120 enrolled

Cancer Pain, Pain, Pain, Intractable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡